These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 37468878)
1. Predictive risk modelling of high resource users under different prescription drug coverage policies in Ontario and Manitoba, Canada. Kornas K; Sarkar J; Fransoo R; Rosella LC BMC Health Serv Res; 2023 Jul; 23(1):768. PubMed ID: 37468878 [TBL] [Abstract][Full Text] [Related]
2. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries. Kennedy J; Morgan S Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719 [TBL] [Abstract][Full Text] [Related]
3. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data. McLeod L; Bereza BG; Shim M; Grootendorst P Open Med; 2011; 5(1):e1-9. PubMed ID: 22046212 [TBL] [Abstract][Full Text] [Related]
4. Socioeconomic differences in prescription drug supplemental coverage in Canada: A repeated cross-sectional study. Guo EX; Sweetman A; Guindon GE Health Policy; 2020 Mar; 124(3):252-260. PubMed ID: 31952864 [TBL] [Abstract][Full Text] [Related]
5. How does complementary private prescription drug insurance coverage affect seniors' use of publicly funded medications? Allin S; Law MR; Laporte A Health Policy; 2013 May; 110(2-3):147-55. PubMed ID: 23522381 [TBL] [Abstract][Full Text] [Related]
6. Estimating Population Benefits of Prevention Approaches Using a Risk Tool: High Resource Users in Ontario, Canada. O'Neill M; Kornas K; Wodchis WP; Rosella LC Healthc Policy; 2021 Feb; 16(3):51-66. PubMed ID: 33720824 [TBL] [Abstract][Full Text] [Related]
7. Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs? Coombes ME; Morgan SG; Barer ML; Pagliccia N Healthc Q; 2004; 7(4):suppl 13-9. PubMed ID: 15540402 [TBL] [Abstract][Full Text] [Related]
8. Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada. Hasan H; Howard F; Morgan SG; Metzger DL; Lo AC; Goddard K; Gill S; Johnson M Healthc Policy; 2014 Feb; 9(3):80-96. PubMed ID: 24726076 [TBL] [Abstract][Full Text] [Related]
9. Associations of health services utilization by prescription drug coverage and immigration category in Ontario, Canada. Antonipillai V; Guindon GE; Sweetman A; Baumann A; Wahoush O; Schwartz L Health Policy; 2021 Oct; 125(10):1311-1321. PubMed ID: 34226053 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults. Pauly NJ; Brown JD J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965 [TBL] [Abstract][Full Text] [Related]
11. Restrictive drug coverage policies can induce substantial drug exposure misclassification in pharmacoepidemiologic studies. Gamble JM; McAlister FA; Johnson JA; Eurich DT Clin Ther; 2012 Jun; 34(6):1379-1386.e3. PubMed ID: 22554975 [TBL] [Abstract][Full Text] [Related]
12. Characterizing high-cost healthcare users among adults with back pain in Ontario, Canada: a population-based cohort study. Wong JJ; Côté P; Tricco AC; Watson T; Rosella LC Pain; 2024 Sep; 165(9):1944-1954. PubMed ID: 38442409 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Utilization, Costs, and Quality of Medicaid vs Subsidized Private Health Insurance for Low-Income Adults. Allen H; Gordon SH; Lee D; Bhanja A; Sommers BD JAMA Netw Open; 2021 Jan; 4(1):e2032669. PubMed ID: 33399859 [TBL] [Abstract][Full Text] [Related]
14. Public prescription drug plan coverage for antiretrovirals and the potential cost to people living with HIV in Canada: a descriptive study. Yoong D; Bayoumi AM; Robinson L; Rachlis B; Antoniou T CMAJ Open; 2018; 6(4):E551-E560. PubMed ID: 30482757 [TBL] [Abstract][Full Text] [Related]
15. Estimated cost of universal public coverage of prescription drugs in Canada. Morgan SG; Law M; Daw JR; Abraham L; Martin D CMAJ; 2015 Apr; 187(7):491-497. PubMed ID: 25780047 [TBL] [Abstract][Full Text] [Related]
16. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382 [TBL] [Abstract][Full Text] [Related]
17. Population-Based Estimates of Health Care Utilization and Expenditures by Adults During the Last 2 Years of Life in Canada's Single-Payer Health System. Rosella LC; Kornas K; Bornbaum C; Huang A; Watson T; Shuldiner J; Wodchis WP JAMA Netw Open; 2020 Apr; 3(4):e201917. PubMed ID: 32236531 [TBL] [Abstract][Full Text] [Related]
18. High-cost health care users in Ontario, Canada: demographic, socio-economic, and health status characteristics. Rosella LC; Fitzpatrick T; Wodchis WP; Calzavara A; Manson H; Goel V BMC Health Serv Res; 2014 Oct; 14():532. PubMed ID: 25359294 [TBL] [Abstract][Full Text] [Related]
19. Frequency and source of prescription eyewear insurance coverage in Ontario: a repeated population-based cross-sectional study using survey data. Nichani P; Trope GE; Buys YM; Markowitz SN; El-Defrawy S; Ngo G; Markowitz M; Jin YP CMAJ Open; 2021; 9(1):E224-E232. PubMed ID: 33731423 [TBL] [Abstract][Full Text] [Related]
20. Patient and Family Financial Burden in Cancer: A Focus on Differences across Four Provinces, and Reduced Spending Including Decisions to Forego Care in Canada. Longo CJ; Maity T; Fitch MI; Young JT Curr Oncol; 2024 May; 31(5):2713-2726. PubMed ID: 38785487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]